ReviewImmunological reviews2008
Autoantibodies to tumor-associated antigens: reporters from the immune system.
Review in Immunological reviews, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.
- Serum autoantibodies in the early detection of esophageal cancer: a systematic review.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Pooled it
- Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.British journal of cancer · 2026Article
- USP38 promotes breast cancer immune evasion and malignant progression by deubiquitinating and stabilizing PD-L1.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- New Insights Into Diffuse Sclerosing Osteomyelitis: Is There a Role of ANA and Vitamin B6?Oral diseases · 2026Article
- Early detection of oral squamous cell carcinoma using five tumor-associated autoantibodies and a Naive Bayes-based machine learning model.Scientific reports · 2026Article
- A panel of four autoantibodies to tumour-associated antigens in patients with prostate cancer and its potential for multi-cancer detection.British journal of cancer · 2026Article
- Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential.Frontiers in oncology · 2026Article
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
- The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint.Journal of experimental & clinical cancer research : CR · 2025Article
- Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study.Frontiers in oncology · 2025Article
- Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer.Frontiers in immunology · 2025Article
- Tumor-Associated Autoantibodies Anti-p53 is Associated with Poor Prognosis in Patients with Lung Adenocarcinoma.Cancer management and research · 2025Article
- Article
- ESCCPred: a machine learning model for diagnostic prediction of early esophageal squamous cell carcinoma using autoantibody profiles.British journal of cancer · 2024Article
- ZPR1 is an immunodiagnostic biomarker and promotes tumor progression in esophageal squamous cell carcinoma.Cancer science · 2024Article
- Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.PeerJ · 2024Article
- Liquid biopsy for early detection of lung cancer.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Association of elevated autoantibody to high expression of GNAS in hepatocellular carcinoma.Heliyon · 2023Article
- A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma.Cancer cell international · 2023Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Although autoantibodies have been recognized as participants in pathogenesis of tissue injury, the collateral role of autoantibodies as reporters from the immune system identifying cellular participants in tumorigenesis has not been fully appreciated. The immune system appears to be capable of sensing aberrant structure, distribution, and function of certain cellular components involved in tumorigenesis and making autoantibody responses to the tumor-associated antigens (TAAs). Autoantibodies to TAAs can report malignant transformation before standard clinical studies and may be useful as early detection biomarkers. The autoantibody response also provides insights into factors related to how cellular components may be rendered immunogenic. As diagnostic biomarkers, specific TAA miniarrays for identifying autoantibody profiles could have sufficient sensitivity in differentiating between types of tumors. Such anti-TAA profiles could also be used to monitor response to therapy. The immune system of cancer patients reveals the immune interactive sites or the autoepitopes of participants in tumorigenesis, and this information should be used in the design of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.